Skip to content
OpenCapital
Get started

Adaptive Biotechnologies ADPT Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Guardant Health logo
Guardant HealthGH
——
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's available for sale securities debt securities current?
Adaptive Biotechnologies (ADPT) reported available for sale securities debt securities current of $140.75M in Q1 2026.
How has Adaptive Biotechnologies's available for sale securities debt securities current changed year-over-year?
Adaptive Biotechnologies's available for sale securities debt securities current decreased by 1.4% year-over-year, from $142.78M to $140.75M.
What is the long-term trend for Adaptive Biotechnologies's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's available for sale securities debt securities current has grown at a -22.6% compound annual growth rate (CAGR), from $564.83M to $156.49M.